Why is the Medlab (ASX:MDC) share price surging 8% today?

The Medlab (ASX: MDC) share price is rising today after the European Patent Office announced its intention to grant Nanocelle a patent.

| More on:
Medical staff wear hero capes, indicting strong shar [price performace for healthcare shares

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Medlab Clinical Ltd (ASX: MDC) share price is rising today after the European Patent Office announced its intention to grant the Australian company a patent for its Nanocelle technology.

The Medlab share price is up 8.33% today to 26 cents per share. 

Medlab is a medical research and development company that's gained a lot of publicity for its innovative medical use of THC, one of the psychoactive compounds in cannabis.

It largely focuses on THC and other cannabinoid products as pain-relievers, but the company is also engaged in researching and formulating novel biotherapeutics or new therapeutic medicines derived from natural organisms.

Its products aim to improve health outcomes in early to moderate stage chronic diseases such as chronic kidney disease, pre-diabetes, and obesity.

What is Medlab's Nanocelle technology?

Medlab is currently focused on the development of Nanocelle technology that can increase the solubility of medicines. It does this through a sub-micron spray, which is administered to the membrane lining the inside of the mouth.

When sprayed, it provides faster and more effective absorption of active ingredients into the bloodstream, without the need for needles or pills.

Medlab considers Nanocelle "a commercially viable platform that offers unique opportunities for partnering with some of the biggest players in the pharma industry". It was behind considerable Medlab share price rises in February this year.

When the European Union grants Medlab's patent, it will be the second granted for Nanocelle, following receipt of an Australian patent in September 2020. Medlab has also filed patent applications in the United States, New Zealand, Singapore, Hong Kong and Canada.

What Medlab management said

Medlab CEO Dr Sean Hall said the patent was the next step in Nanocelle's expansion into worldwide markets.

Receiving notice of intent from the European Patent Office represents another important validation of our NanoCelle drug delivery platform, offering Nanocelle protection in one of the world's largest markets.

The grant will not only bolster the competitive advantage of our pharmaceutical and nutraceutical portfolio, it will also support our robust research and development pipeline and commercial partnering focus. We are delighted with this recognition.

Medlab share price snapshot

The Medlab share price has been on a rocky road, rising from 15 cents in July 2020 to more than 36 cents in January this year. It's gained 6% in 2021 so far but lost 8% over the past 12 months and is down 40% against the S&P/ASX 200 Index (ASX: XJO).

Motley Fool contributor Lucas Radbourne-Pugh has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Male doctor in a lab coat working at laptop looking serious.
Healthcare Shares

This bombshell for ASX healthcare shares could hit 6 million Australians

This could have a large impact.

Read more »

Two scientists in a Rhythm Biosciences lab cheer while looking at results on a computer.
Healthcare Shares

2 ASX healthcare shares having a stellar run today

The ASX healthcare sector is down today but these two stocks are bucking the trend.

Read more »

A company manager presents the ASX company earnings report to shareholders at an AGM.
Healthcare Shares

Why this $13 billion ASX 200 healthcare stock is surging today

A change in sentiment for the healthcare player.

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

This ASX 200 stock hit a 52-week low and a top broker thinks it can rebound

Patient investors may see this stock make a pleasing recovery.

Read more »

A couple smile as they look at a pregnancy test.
Healthcare Shares

Why this sold-off ASX healthcare share could be an exciting dividend buy

This could be a healthy stock for dividends.

Read more »

a smiling woman sits at her computer at home with a coffee alongside her, as if pleased with her investments.
Healthcare Shares

Is CSL the best ASX 100 share to buy now?

Bell Potter has good things to say about this blue chip star.

Read more »

Scientists in a laboratory look at a computer screen with anticipation on their faces representing a potential change in the performance of ASX biotech shares in FY23
Healthcare Shares

Down 10% in a month, are CSL shares feeling the sting of a potential disruption?

Brokers are still bullish.

Read more »

One girl leapfrogs over her friend's back.
Healthcare Shares

Doubled in a year! Does this booming ASX share have another 24% upside?

Let's take a look.

Read more »